Cargando…

Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism

Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishrat, Tauheed, Kozak, Anna, Alhusban, Ahmed, Pillai, Bindu, Johnson, Maribeth H., El-Remessy, Azza B., Ergul, Adviye, Fagan, Susan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134816/
https://www.ncbi.nlm.nih.gov/pubmed/25147751
http://dx.doi.org/10.1155/2014/560491
_version_ 1782330915596271616
author Ishrat, Tauheed
Kozak, Anna
Alhusban, Ahmed
Pillai, Bindu
Johnson, Maribeth H.
El-Remessy, Azza B.
Ergul, Adviye
Fagan, Susan C.
author_facet Ishrat, Tauheed
Kozak, Anna
Alhusban, Ahmed
Pillai, Bindu
Johnson, Maribeth H.
El-Remessy, Azza B.
Ergul, Adviye
Fagan, Susan C.
author_sort Ishrat, Tauheed
collection PubMed
description Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism.
format Online
Article
Text
id pubmed-4134816
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41348162014-08-21 Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism Ishrat, Tauheed Kozak, Anna Alhusban, Ahmed Pillai, Bindu Johnson, Maribeth H. El-Remessy, Azza B. Ergul, Adviye Fagan, Susan C. Stroke Res Treat Research Article Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism. Hindawi Publishing Corporation 2014 2014-07-24 /pmc/articles/PMC4134816/ /pubmed/25147751 http://dx.doi.org/10.1155/2014/560491 Text en Copyright © 2014 Tauheed Ishrat et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ishrat, Tauheed
Kozak, Anna
Alhusban, Ahmed
Pillai, Bindu
Johnson, Maribeth H.
El-Remessy, Azza B.
Ergul, Adviye
Fagan, Susan C.
Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title_full Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title_fullStr Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title_full_unstemmed Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title_short Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
title_sort role of matrix metalloproteinase activity in the neurovascular protective effects of angiotensin antagonism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134816/
https://www.ncbi.nlm.nih.gov/pubmed/25147751
http://dx.doi.org/10.1155/2014/560491
work_keys_str_mv AT ishrattauheed roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT kozakanna roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT alhusbanahmed roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT pillaibindu roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT johnsonmaribethh roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT elremessyazzab roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT erguladviye roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism
AT fagansusanc roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism